$TGTX
TG THERAPEUTICS, INC.

2022 Q4 Form 10-Q Financial Statement

#000155837022017180 Filed on November 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $80.00K $94.00K $2.030M
YoY Change -96.55% -95.37% 5242.11%
Cost Of Revenue $3.000K $2.000K $292.0K
YoY Change -98.57% -99.32%
Gross Profit $77.00K $92.00K $1.738M
YoY Change -96.35% -94.71%
Gross Profit Margin 96.25% 97.87% 85.62%
Selling, General & Admin $22.50M $14.25M $34.90M
YoY Change -30.57% -59.16% -1.12%
% of Gross Profit 29225.97% 15493.48% 2008.0%
Research & Development $29.64M $20.80M $51.97M
YoY Change -52.69% -59.97% 2.98%
% of Gross Profit 38487.01% 22609.78% 2990.05%
Depreciation & Amortization $73.00K $76.00K $76.00K
YoY Change -8.75% 0.0% 52.0%
% of Gross Profit 94.81% 82.61% 4.37%
Operating Expenses $52.14M $35.06M $87.16M
YoY Change -45.15% -59.78% 1.63%
Operating Profit -$52.06M -$34.96M -$85.13M
YoY Change -43.99% -58.93% -0.69%
Interest Expense -$2.862M $1.648M $1.038M
YoY Change 165.25% 58.77% -35.53%
% of Operating Profit
Other Income/Expense, Net $1.930M -$855.0K -$509.0K
YoY Change 180.52% 67.98% -64.68%
Pretax Income -$52.99M -$35.82M -$85.64M
YoY Change -43.22% -58.17% -1.75%
Income Tax
% Of Pretax Income
Net Earnings -$52.99M -$35.82M -$85.64M
YoY Change -43.22% -58.17% -1.75%
Net Earnings / Revenue -66242.5% -38104.26% -4218.57%
Basic Earnings Per Share -$0.26 -$0.65
Diluted Earnings Per Share -$0.39 -$0.26 -$647.0K
COMMON SHARES
Basic Shares Outstanding 145.3M 135.3M 142.8M
Diluted Shares Outstanding 135.3M 132.4M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $161.7M $175.9M $356.9M
YoY Change -48.64% -50.7% 40.38%
Cash & Equivalents $102.3M $109.9M $326.5M
Short-Term Investments $59.37M $66.08M $30.34M
Other Short-Term Assets $2.359M $2.954M $2.502M
YoY Change -18.2% 18.07% 290.33%
Inventory $0.00
Prepaid Expenses
Receivables $0.00 $0.00 $1.384M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $168.3M $182.9M $371.8M
YoY Change -49.16% -50.8% 42.81%
LONG-TERM ASSETS
Property, Plant & Equipment $307.0K $376.0K $600.0K
YoY Change -48.83% -37.33% 58.73%
Goodwill $799.0K $799.0K $799.0K
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $12.40M $21.77M $24.55M
YoY Change -65.09% -11.34%
Other Assets $1.273M $1.269M $1.263M
YoY Change 0.71% 0.48% -2.85%
Total Long-Term Assets $25.30M $34.97M $37.91M
YoY Change -48.01% -7.75% 180.36%
TOTAL ASSETS
Total Short-Term Assets $168.3M $182.9M $371.8M
Total Long-Term Assets $25.30M $34.97M $37.91M
Total Assets $193.6M $217.9M $409.7M
YoY Change -49.01% -46.82% 49.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $42.02M $29.73M $44.70M
YoY Change -18.08% -33.5% 28.82%
Accrued Expenses $10.01M $5.914M $14.33M
YoY Change -13.7% -58.72% 113.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $16.00M
YoY Change -100.0% -100.0% 9.66%
Total Short-Term Liabilities $53.20M $36.45M $87.66M
YoY Change -18.63% -58.42% 12.86%
LONG-TERM LIABILITIES
Long-Term Debt $71.14M $70.04M $0.00
YoY Change 6.51% -100.0%
Other Long-Term Liabilities $10.65M $10.93M $10.52M
YoY Change 3.35% 3.9% 0.14%
Total Long-Term Liabilities $71.14M $70.04M $10.52M
YoY Change 6.51% 566.08% -30.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.20M $36.45M $87.66M
Total Long-Term Liabilities $71.14M $70.04M $10.52M
Total Liabilities $135.0M $117.4M $98.17M
YoY Change -5.26% 19.6% -4.87%
SHAREHOLDERS EQUITY
Retained Earnings -$1.527B -$1.500B -$1.200B
YoY Change 14.93% 25.0% 34.47%
Common Stock $146.0K $145.0K $143.0K
YoY Change 2.1% 1.4% 10.85%
Preferred Stock
YoY Change
Treasury Stock (at cost) $200.0K $234.0K
YoY Change -14.53% 0.0%
Treasury Stock Shares $41.31K $41.31K
Shareholders Equity $58.59M $100.5M $311.5M
YoY Change
Total Liabilities & Shareholders Equity $193.6M $217.9M $409.7M
YoY Change -49.01% -46.82% 49.6%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$52.99M -$35.82M -$85.64M
YoY Change -43.22% -58.17% -1.75%
Depreciation, Depletion And Amortization $73.00K $76.00K $76.00K
YoY Change -8.75% 0.0% 52.0%
Cash From Operating Activities -$23.87M -$34.50M -$67.20M
YoY Change -72.53% -48.67% 18.88%
INVESTING ACTIVITIES
Capital Expenditures $3.000K -$4.000K -$79.00K
YoY Change -103.75% -94.94% -12.22%
Acquisitions
YoY Change
Other Investing Activities $16.27M -$2.986M -$552.0K
YoY Change 383.14% 440.94% -103.68%
Cash From Investing Activities $16.27M -$2.990M -$631.0K
YoY Change 394.8% 373.85% -104.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 49.00K 275.0K -7.361M
YoY Change -99.91% -103.74% -120.87%
NET CHANGE
Cash From Operating Activities -23.87M -34.50M -67.20M
Cash From Investing Activities 16.27M -2.990M -631.0K
Cash From Financing Activities 49.00K 275.0K -7.361M
Net Change In Cash -7.552M -37.21M -75.19M
YoY Change -72.66% -50.51% 1084.14%
FREE CASH FLOW
Cash From Operating Activities -$23.87M -$34.50M -$67.20M
Capital Expenditures $3.000K -$4.000K -$79.00K
Free Cash Flow -$23.87M -$34.49M -$67.12M
YoY Change -72.51% -48.61% 18.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
135327035
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.93
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
132353119
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134839207
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
132109912
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Central Index Key
EntityCentralIndexKey
0001001316
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32639
dei Entity Registrant Name
EntityRegistrantName
TG THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-3898269
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-3898269
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Gansevoort Street, 9th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10014
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
554-4484
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TGTX
dei Trading Symbol
TradingSymbol
TGTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
145341967
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109860000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
298887000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
66082000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1389000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
143000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
15876000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9079000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
330965000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1269000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1264000
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
21766000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
35533000
CY2022Q3 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
4026000
CY2021Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
11929000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2954000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2884000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
182922000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8629000
CY2022Q3 tgtx Leasehold Interest
LeaseholdInterest
1680000
CY2021Q4 tgtx Leasehold Interest
LeaseholdInterest
1839000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
376000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
600000
CY2022Q3 us-gaap Goodwill
Goodwill
799000
CY2021Q4 us-gaap Goodwill
Goodwill
799000
CY2022Q3 us-gaap Assets
Assets
217891000
CY2021Q4 us-gaap Assets
Assets
379629000
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
29726000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
51294000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
807000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1512000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
975000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1616000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1437000
CY2022Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
4298000
CY2021Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
10166000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
36447000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65384000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
343000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
457000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
70038000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
66788000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10582000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9847000
CY2022Q3 us-gaap Liabilities
Liabilities
117410000
CY2021Q4 us-gaap Liabilities
Liabilities
142476000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
145399144
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
143292043
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
145357835
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
143250734
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
145000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1574609000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1565942000
CY2022Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2022Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
234000
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
234000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1474039000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1328698000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
100481000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
237153000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
217891000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
379629000
CY2022Q3 us-gaap Revenues
Revenues
94000
CY2021Q3 us-gaap Revenues
Revenues
2030000
us-gaap Revenues
Revenues
2705000
us-gaap Revenues
Revenues
4368000
CY2022Q3 tgtx Cost Of Product Revenue
CostOfProductRevenue
2000
CY2021Q3 tgtx Cost Of Product Revenue
CostOfProductRevenue
292000
tgtx Cost Of Product Revenue
CostOfProductRevenue
262000
tgtx Cost Of Product Revenue
CostOfProductRevenue
580000
CY2022Q3 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
3249000
CY2021Q3 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
4534000
tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
7471000
tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
19061000
CY2022Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
17552000
CY2021Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
47433000
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
88246000
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
140872000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20801000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51967000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95717000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
159933000
CY2022Q3 tgtx Non Cash Compensation Selling General And Administrative Expenses
NonCashCompensationSellingGeneralAndAdministrativeExpenses
3740000
CY2021Q3 tgtx Non Cash Compensation Selling General And Administrative Expenses
NonCashCompensationSellingGeneralAndAdministrativeExpenses
9463000
tgtx Non Cash Compensation Selling General And Administrative Expenses
NonCashCompensationSellingGeneralAndAdministrativeExpenses
663000
tgtx Non Cash Compensation Selling General And Administrative Expenses
NonCashCompensationSellingGeneralAndAdministrativeExpenses
27857000
CY2022Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
10514000
CY2021Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
25436000
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
46840000
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
67821000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14254000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34899000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47503000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
95678000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
35057000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
87158000
us-gaap Operating Expenses
OperatingExpenses
143482000
us-gaap Operating Expenses
OperatingExpenses
256191000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-34963000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17970000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5772000
us-gaap Operating Income Loss
OperatingIncomeLoss
-140777000
us-gaap Operating Income Loss
OperatingIncomeLoss
-251823000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1648000
CY2021Q3 us-gaap Interest Expense
InterestExpense
1038000
us-gaap Interest Expense
InterestExpense
7329000
us-gaap Interest Expense
InterestExpense
4559000
CY2022Q3 us-gaap Other Income
OtherIncome
793000
CY2021Q3 us-gaap Other Income
OtherIncome
529000
us-gaap Other Income
OtherIncome
2765000
us-gaap Other Income
OtherIncome
1619000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-85128000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-855000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-509000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4564000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2940000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-35818000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-85637000
us-gaap Profit Loss
ProfitLoss
-145341000
us-gaap Profit Loss
ProfitLoss
-254763000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.93
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135327035
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
132353119
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
134839207
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
132109912
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
519350000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
CY2021Q1 tgtx Offering Costs
OfferingCosts
-183000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
16618000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-90628000
CY2021Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
445285000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
16304000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-78497000
CY2021Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
383130000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50000
CY2021Q3 tgtx Offering Costs
OfferingCosts
-22000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
13996000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-85637000
CY2021Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
311517000
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
237153000
tgtx Proceeds From Maturities
ProceedsFromMaturities
40000000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
125000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2121000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-69013000
CY2022Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
170386000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
135000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
1000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
-975000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-40510000
CY2022Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
129035000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
275000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
1000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
6989000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-35818000
CY2022Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
100481000
us-gaap Profit Loss
ProfitLoss
-145341000
us-gaap Profit Loss
ProfitLoss
-254763000
us-gaap Share Based Compensation
ShareBasedCompensation
8134000
us-gaap Share Based Compensation
ShareBasedCompensation
46918000
us-gaap Depreciation
Depreciation
230000
us-gaap Depreciation
Depreciation
202000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
172000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-421000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1383000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
694000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
159000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
159000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2205000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1422000
tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
241000
tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
315000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-7842000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
7255000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1389000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1384000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-27436000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
12090000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1741000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1507000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1403000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-5293000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-114000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-114000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-152300000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-208725000
tgtx Proceeds From Maturities
ProceedsFromMaturities
67005000
tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
103276000
tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
43299000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16337769
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13126038
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16337769
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13126038
CY2021Q3 tgtx Revenue Gross
RevenueGross
2528000
tgtx Revenue Gross
RevenueGross
4119000
tgtx Revenue Gross
RevenueGross
5167000
CY2022Q3 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
4000
CY2021Q3 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
292000
us-gaap Administrative Fees Expense
AdministrativeFeesExpense
376000
us-gaap Administrative Fees Expense
AdministrativeFeesExpense
487000
CY2022Q3 tgtx Trade Discounts And Allowances
TradeDiscountsAndAllowances
-7000
CY2021Q3 tgtx Trade Discounts And Allowances
TradeDiscountsAndAllowances
128000
tgtx Trade Discounts And Allowances
TradeDiscountsAndAllowances
182000
tgtx Trade Discounts And Allowances
TradeDiscountsAndAllowances
222000
CY2022Q3 tgtx Government Rebates And Co Payment Assistance
GovernmentRebatesAndCoPaymentAssistance
-3000
CY2021Q3 tgtx Government Rebates And Co Payment Assistance
GovernmentRebatesAndCoPaymentAssistance
103000
tgtx Government Rebates And Co Payment Assistance
GovernmentRebatesAndCoPaymentAssistance
279000
tgtx Government Rebates And Co Payment Assistance
GovernmentRebatesAndCoPaymentAssistance
179000
CY2022Q3 tgtx Sales Returns And Allowances
SalesReturnsAndAllowances
-50000
CY2021Q3 tgtx Sales Returns And Allowances
SalesReturnsAndAllowances
13000
tgtx Sales Returns And Allowances
SalesReturnsAndAllowances
691000
tgtx Sales Returns And Allowances
SalesReturnsAndAllowances
25000
CY2022Q3 tgtx Gross To Net Adjustments
GrossToNetAdjustments
-56000
CY2021Q3 tgtx Gross To Net Adjustments
GrossToNetAdjustments
536000
tgtx Gross To Net Adjustments
GrossToNetAdjustments
1528000
tgtx Gross To Net Adjustments
GrossToNetAdjustments
913000
CY2022Q3 tgtx Net Product Revenue
NetProductRevenue
56000
CY2021Q3 tgtx Net Product Revenue
NetProductRevenue
1992000
tgtx Net Product Revenue
NetProductRevenue
2591000
tgtx Net Product Revenue
NetProductRevenue
4254000
CY2022Q3 tgtx Gross Net Accruals
GrossNetAccruals
300000
CY2022Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
87848000
CY2022Q3 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
1748000
CY2022Q3 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
86100000
CY2021Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
51409000
CY2021Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
164000
CY2021Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
51245000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
360000
tgtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings
802000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-1043000
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
119000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
7000000.0
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
14000000.0
us-gaap Share Based Compensation
ShareBasedCompensation
8100000
us-gaap Share Based Compensation
ShareBasedCompensation
46900000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
70038000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
66788000
CY2021Q4 tgtx Paid In Kind Interest Rate
PaidInKindInterestRate
0.0345
CY2022Q3 us-gaap Other Long Term Debt
OtherLongTermDebt
70000000
CY2021Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
70000000
CY2022Q3 tgtx End Of Term Fee
EndOfTermFee
6031000
CY2021Q4 tgtx End Of Term Fee
EndOfTermFee
5140000
CY2022Q3 tgtx Long Term Debt Gross
LongTermDebtGross
76031000
CY2021Q4 tgtx Long Term Debt Gross
LongTermDebtGross
75140000
CY2022Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
5993000
CY2021Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
7377000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
70038000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
67763000
CY2022Q3 tgtx Long Term Debt Excluding Principal Payments
LongTermDebtExcludingPrincipalPayments
70038000
CY2021Q4 tgtx Long Term Debt Excluding Principal Payments
LongTermDebtExcludingPrincipalPayments
67763000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
975000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
321000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36282000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3620000
us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
-975000
us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
-14590000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
535000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
216000
tgtx Repayment Of Offering Costs
RepaymentOfOfferingCosts
204000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-440000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14578000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-189022000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-226923000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
300151000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
554698000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111129000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
327775000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109860000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
326512000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
1269000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
1263000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111129000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
327775000
us-gaap Interest Paid Net
InterestPaidNet
3908000
us-gaap Interest Paid Net
InterestPaidNet
2698000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1500000000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
197700000
CY2022Q3 tgtx Operating Lease Liability Incremental Borrowing Rate
OperatingLeaseLiabilityIncrementalBorrowingRate
12198000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
12200000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9100000
CY2022Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1062000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
532000
us-gaap Operating Lease Cost
OperatingLeaseCost
2100000
us-gaap Operating Lease Cost
OperatingLeaseCost
1595000
CY2022Q3 us-gaap Lease Cost
LeaseCost
1062000
CY2021Q3 us-gaap Lease Cost
LeaseCost
532000
us-gaap Lease Cost
LeaseCost
2100000
us-gaap Lease Cost
LeaseCost
1595000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1616000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1437000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10582000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9847000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
12198000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11284000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
591000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2375000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2388000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2100000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2080000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
8436000

Files In Submission

Name View Source Status
0001558370-22-017180-index-headers.html Edgar Link pending
0001558370-22-017180-index.html Edgar Link pending
0001558370-22-017180.txt Edgar Link pending
0001558370-22-017180-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tgtx-20220930.xsd Edgar Link pending
tgtx-20220930x10q.htm Edgar Link pending
tgtx-20220930xex31d1.htm Edgar Link pending
tgtx-20220930xex31d2.htm Edgar Link pending
tgtx-20220930xex32d1.htm Edgar Link pending
tgtx-20220930xex32d2.htm Edgar Link pending
tgtx-20220930_def.xml Edgar Link unprocessable
tgtx-20220930_lab.xml Edgar Link unprocessable
tgtx-20220930_pre.xml Edgar Link unprocessable
tgtx-20220930x10q_htm.xml Edgar Link completed
tgtx-20220930_cal.xml Edgar Link unprocessable